Telomir Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on March 23, 2026, at the Company's 2025 Annual Meeting of Stockholders. Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) is an emerging growth company incorporated in Florida. The filing details the approval of seven proposals by shareholders, including a significant acquisition, amendments to equity incentive plans, and changes to corporate bylaws.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance actions and shareholder voting results rather than financial performance metrics.
Material Changes and Corporate Actions
- Acquisition Approval: Shareholders approved the acquisition of Teli Pharmaceuticals, Inc. This transaction involves the issuance of shares representing more than 20% of the Company's outstanding common stock immediately prior to the acquisition, requiring approval under Nasdaq Listing Rule 5635(a).
- Equity Plan Amendment: The 2023 Omnibus Incentive Plan was amended to increase the share reserve from 6,500,000 to 11,500,000 shares. The amendment also authorizes the repricing of options and stock appreciation rights (SARs), including reducing exercise or grant prices.
- Bylaw Amendment: The quorum requirement for shareholder meetings was reduced to one-third of the outstanding shares.
- Board Elections: Erez Aminov, Matthew Whalen, Edward MacPherson, and Matthew Del Giudice, M.D., were elected as directors.
- Auditor Ratification: Salberg & Company, P.A. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Outlook, Risks, and Voting Results
All seven proposals submitted to shareholders were approved. The voting participation was approximately 51.16% of outstanding shares (17,589,062 shares represented). Notable voting statistics include:
- Acquisition Proposal (Proposal 1): 17,022,302 votes For; 116,825 votes Against.
- Equity Plan Amendment (Proposal 4): 15,397,036 votes For; 1,721,558 votes Against.
- Bylaw Amendment (Proposal 5): 15,390,044 votes For; 1,766,283 votes Against.
The filing does not contain specific management commentary on future financial guidance or detailed risk factors beyond the standard disclosures associated with the acquisition and equity plan changes.
Investor Verification Checklist
- Verify the definitive proxy statement filed on February 19, 2026, for detailed terms of the Teli Pharmaceuticals, Inc. acquisition.
- Review the amended 2023 Omnibus Incentive Plan (Exhibit 10.1) to understand the specific mechanics and limitations of the new option repricing authority.
- Confirm the impact of the 11,500,000 share reserve increase on potential future dilution.
- Monitor subsequent filings for the closing date and final consideration details of the Teli Pharmaceuticals acquisition.